share_log

Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year

Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year

諾華股份公司表示，Novartis Cosentyx獲得CHMP對化膿性汗腺炎的積極看法；意見爲近十年來化膿性汗腺炎的首個新治療選擇鋪平了道路；美國食品藥品管理局預計將於今年晚些時候做出監管決定
Benzinga ·  2023/04/27 23:15

Novartis AG Says Novartis Cosentyx Gains Positive CHMP Opinion For Hidradenitis Suppurativa; Opinion Paves Way For First New Treatment Option In Hidradenitis Suppurativa In Nearly A Decade; Regulatory Decision From U.S. FDA Expected Later This Year

諾華股份公司表示，Novartis Cosentyx獲得CHMP對化膿性汗腺炎的積極看法；意見爲近十年來化膿性汗腺炎的首個新治療選擇鋪平了道路；美國食品藥品管理局預計將於今年晚些時候做出監管決定

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論